Polyrizon Ltd. (PLRZ)

$1.55 -0.09 (-5.49%)
Market Cap N/A
Revenue (ttm) N/A
Net Income (ttm) N/A
EPS (ttm) N/A
PE Ratio N/A
Forward PE N/A
Profit Margin N/A
Debt to Equity Ratio N/A
Volume 1,429,814
Avg Vol N/A
Day's Range N/A - N/A
Shares Out N/A
Stochastic %K N/A
Beta N/A
Analysts N/A
Price Target N/A

Company Profile

Polyrizon Ltd., a biotech company, engages in the development of medical device hydrogels in the form of nasal sprays in Israel. The company uses its proprietary technology to develop its products comprising Capture and Contain, a barrier against a range of allergen particulates and viruses; and Trap and Target for nasal delivery of active pharmaceutical ingredients. It also develops PL-14, a nasal allergies blocker; and PL-16 for influenza blockers. Polyrizon Ltd. was incorporated in 2005 is he...

Industry: Biotechnology
Sector: Healthcare
Phone: 972 9 374 0120
Address:
5 HaPnina Street, Ra'anana, Israel
Tbirdyguy
Tbirdyguy May. 8 at 5:02 PM
$PLRZ looks like the market has been anticipating something big over the last 3 weeks. Solid moves today after abismal volume all week. Testing recent heights in the 17s. A pr sends this well into the 20s
0 · Reply
Shakyaasha
Shakyaasha May. 5 at 7:30 PM
$PLRZ
1 · Reply
InvestingSpaceman
InvestingSpaceman May. 4 at 9:22 PM
$BLMZ $PLRZ $BTCT.X $BTOG HL
0 · Reply
luminouslumens
luminouslumens May. 2 at 8:33 PM
$PLRZ $EUDA $ONEG $AKAN A few multi-day movers to keep an eye on Monday
0 · Reply
Tbirdyguy
Tbirdyguy Apr. 28 at 2:33 PM
$PLRZ fucking
0 · Reply
labububub
labububub Apr. 28 at 2:13 PM
$PLRZ
0 · Reply
patrick1956
patrick1956 Apr. 28 at 2:29 AM
$PLRZ ...European submission fail...FDA is not accepting their submission with any success...thus the submission at European...now both fail....look for this to head back under $10. ..imo
1 · Reply
Stock_Catcher
Stock_Catcher Apr. 28 at 2:11 AM
Treasure Tuesday Watchlist Pt.5 $OPEN $GNS $ASST $DVLT $PLRZ Let's Dominate Tomorrow
0 · Reply
StockConsultant
StockConsultant Apr. 28 at 12:14 AM
$PLRZ Polyrizon stock, watch for a range breakout at https://stockconsultant.com/?PLRZ
0 · Reply
stocktrade77
stocktrade77 Apr. 27 at 11:11 PM
$PLRZ something cooking here, taking starter for a swing to 20 / 23 - will scale in as it goes up
0 · Reply
Latest News on PLRZ
Pulse Equity: Emerging Outbreaks - Polyrizon's Approach to Broad and Rapidly Deployable Protection

May 11, 2026, 7:25 AM EDT - 2 days ago

Pulse Equity: Emerging Outbreaks - Polyrizon's Approach to Broad and Rapidly Deployable Protection

Polyrizon amends patent application claims for intranasal drug delivery platform

2026-05-04T13:47:12.000Z - 8 days ago

Polyrizon amends patent application claims for intranasal drug delivery platform

Polyrizon Announces U.S. Patent Expansion for Its Intranasal Drug Delivery Platform

May 4, 2026, 8:45 AM EDT - 9 days ago

Polyrizon Announces U.S. Patent Expansion for Its Intranasal Drug Delivery Platform

Polyrizon Ltd trading halted, volatility trading pause

2026-04-28T14:31:03.000Z - 14 days ago

Polyrizon Ltd trading halted, volatility trading pause

Polyrizon Ltd trading resumes

2026-04-28T14:25:09.000Z - 14 days ago

Polyrizon Ltd trading resumes

Polyrizon files European patent application for Trap & Target platform

2026-04-27T13:57:32.000Z - 15 days ago

Polyrizon files European patent application for Trap & Target platform

Polyrizon Announces Filing of European Patent Application for Its Breakthrough Drug Delivery Platform

Apr 27, 2026, 9:28 AM EDT - 15 days ago

Polyrizon Announces Filing of European Patent Application for Its Breakthrough Drug Delivery Platform

Polyrizon files to sell 0.5M shares of common stock for holders

2026-04-23T23:30:28.000Z - 19 days ago

Polyrizon files to sell 0.5M shares of common stock for holders

Polyrizon Ltd. Announces Closing of $3.5 Million Registered Direct and Private Placements

Apr 8, 2026, 4:16 PM EDT - 4 weeks ago

Polyrizon Ltd. Announces Closing of $3.5 Million Registered Direct and Private Placements

Polyrizon Provides 2025 and Recent Highlights

Mar 26, 2026, 9:23 AM EDT - 6 weeks ago

Polyrizon Provides 2025 and Recent Highlights

Polyrizon Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2025

Mar 25, 2026, 5:25 PM EDT - 6 weeks ago

Polyrizon Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2025

Polyrizon to acquire 20% stake in Colugo for up to $6M

2026-03-24T13:05:32.000Z - 7 weeks ago

Polyrizon to acquire 20% stake in Colugo for up to $6M

Polyrizon Intends to Acquire up to 20% Stake in Colugo, Developer of Advanced eVTOL Drones for Defense and Urban Air Mobility Applications

Mar 24, 2026, 8:47 AM EDT - 7 weeks ago

Polyrizon Intends to Acquire up to 20% Stake in Colugo, Developer of Advanced eVTOL Drones for Defense and Urban Air Mobility Applications

Biotech Alert: Searches spiking for these stocks today

2026-03-17T15:51:34.000Z - 2 months ago

Biotech Alert: Searches spiking for these stocks today

Polyrizon signs agreement with research organization for clinical development

2026-03-17T12:35:48.000Z - 2 months ago

Polyrizon signs agreement with research organization for clinical development

Polyrizon Signs an Agreement with Leading Global Preclinical CRO as Part of Clinical Development Program

Mar 17, 2026, 8:25 AM EDT - 2 months ago

Polyrizon Signs an Agreement with Leading Global Preclinical CRO as Part of Clinical Development Program

Polyrizon announces production of GMP batch of Clinical Trial Material

2026-03-10T12:09:52.000Z - 2 months ago

Polyrizon announces production of GMP batch of Clinical Trial Material

Polyrizon Announces GMP Manufacturing of Clinical Trial Material (CTM) with Eurofins CDMO AmatsiAquitaine S.A.S for Planned U.S. Clinical Study

Mar 10, 2026, 7:55 AM EDT - 2 months ago

Polyrizon Announces GMP Manufacturing of Clinical Trial Material (CTM) with Eurofins CDMO AmatsiAquitaine S.A.S for Planned U.S. Clinical Study

Polyrizon announces results from study evaluating profile of naloxone formula

2026-02-26T13:40:23.000Z - 2 months ago

Polyrizon announces results from study evaluating profile of naloxone formula

Polyrizon Announces Successful Study of its Naloxone Formulation Demonstrating Enhanced Nasal Deposition Profile Versus Commercial Reference Product

Feb 26, 2026, 8:12 AM EST - 2 months ago

Polyrizon Announces Successful Study of its Naloxone Formulation Demonstrating Enhanced Nasal Deposition Profile Versus Commercial Reference Product

Moonage Media Spotlights Polyrizon (Nasdaq: PLRZ): Unveils NASARIX™, Drug-Free Allergy Blocker

Feb 17, 2026, 11:32 AM EST - 3 months ago

Moonage Media Spotlights Polyrizon (Nasdaq: PLRZ): Unveils NASARIX™, Drug-Free Allergy Blocker

Polyrizon intends to acquire a 51% stake in Arrow Aviation

2026-02-10T12:10:14.000Z - 3 months ago

Polyrizon intends to acquire a 51% stake in Arrow Aviation

Polyrizon Intends to Secure Controlling Stake in Profitable Private Jet Operator

Feb 10, 2026, 6:55 AM EST - 3 months ago

Polyrizon Intends to Secure Controlling Stake in Profitable Private Jet Operator

Clearmind, Polyrizon enter development agreement for intranasal MEAI formulation

2026-02-06T13:01:07.000Z - 3 months ago

Clearmind, Polyrizon enter development agreement for intranasal MEAI formulation

CMND

Clearmind, Polyrizon enter development agreement for intranasal MEAI formulation

2026-02-06T13:00:53.000Z - 3 months ago

Clearmind, Polyrizon enter development agreement for intranasal MEAI formulation

CMND

Polyrizon Signs an Agreement to Develop Intranasal Proprietary Non-Hallucinogenic Neuroplastogen Formulation

Feb 6, 2026, 7:55 AM EST - 3 months ago

Polyrizon Signs an Agreement to Develop Intranasal Proprietary Non-Hallucinogenic Neuroplastogen Formulation

Biotech Alert: Searches spiking for these stocks today

2026-02-04T16:40:13.000Z - 3 months ago

Biotech Alert: Searches spiking for these stocks today

Polyrizon intends to acquire 51% stake in Arrow Aviation for NIS 18M

2026-02-04T12:15:20.000Z - 3 months ago

Polyrizon intends to acquire 51% stake in Arrow Aviation for NIS 18M

Polyrizon Intends to Acquire 51% Stake in Global Private Aviation Company

Feb 4, 2026, 7:12 AM EST - 3 months ago

Polyrizon Intends to Acquire 51% Stake in Global Private Aviation Company

Polyrizon initiates key usability study program for NASARIX

2026-01-22T14:31:23.000Z - 3 months ago

Polyrizon initiates key usability study program for NASARIX

Polyrizon Advances Regulatory Path with Initiation of Usability Study Program for NASARIX™ Allergy Blocker

Jan 22, 2026, 9:25 AM EST - 3 months ago

Polyrizon Advances Regulatory Path with Initiation of Usability Study Program for NASARIX™ Allergy Blocker

Polyrizon announces board authorized exploration of investment opportunities

2026-01-13T13:55:15.000Z - 4 months ago

Polyrizon announces board authorized exploration of investment opportunities

Polyrizon to Explore Revenue-Generating Investment Opportunities in High-Growth Sectors, Leveraging Strong Cash Position and Debt-Free Balance Sheet

Jan 13, 2026, 8:39 AM EST - 4 months ago

Polyrizon to Explore Revenue-Generating Investment Opportunities in High-Growth Sectors, Leveraging Strong Cash Position and Debt-Free Balance Sheet

Polyrizon completes branding process for PL-14 allergy blocker

2026-01-08T14:01:28.000Z - 4 months ago

Polyrizon completes branding process for PL-14 allergy blocker

Polyrizon Completes Branding Process for PL-14 Allergy Blocker with Brand Name NASARIX™

Jan 8, 2026, 8:45 AM EST - 4 months ago

Polyrizon Completes Branding Process for PL-14 Allergy Blocker with Brand Name NASARIX™

Polyrizon Announces New Pre-Clinical Results: PL-14 Demonstrates Significant Allergen-Blocking Performance Compared to a Standard Comparator

Jan 5, 2026, 9:07 AM EST - 4 months ago

Polyrizon Announces New Pre-Clinical Results: PL-14 Demonstrates Significant Allergen-Blocking Performance Compared to a Standard Comparator

As Flu Surge Continues, Polyrizon's Nasal Spray Emerges as Potential Extra Shield Solution for Both Vaccinated and Unvaccinated

Jan 2, 2026, 8:30 AM EST - 4 months ago

As Flu Surge Continues, Polyrizon's Nasal Spray Emerges as Potential Extra Shield Solution for Both Vaccinated and Unvaccinated

Polyrizon to Explore Revenue-Generating Real Asset Opportunities, Leveraging Strong Cash Position and Debt-Free Balance Sheet

Dec 29, 2025, 7:20 AM EST - 4 months ago

Polyrizon to Explore Revenue-Generating Real Asset Opportunities, Leveraging Strong Cash Position and Debt-Free Balance Sheet

Polyrizon Submits Pre-Request for Designation to FDA for PL-16 Viral Blocker Designed to Reduce the Exposure to Influenza and Cold Viruses

Dec 19, 2025, 8:20 AM EST - 5 months ago

Polyrizon Submits Pre-Request for Designation to FDA for PL-16 Viral Blocker Designed to Reduce the Exposure to Influenza and Cold Viruses

Polyrizon Announces Promising Permeation Kinetics Supporting Advancement of Its Intranasal Naloxone Hydrogel Program

Dec 11, 2025, 8:15 AM EST - 5 months ago

Polyrizon Announces Promising Permeation Kinetics Supporting Advancement of Its Intranasal Naloxone Hydrogel Program

Polyrizon Completes FDA Pre-Submission Meeting for PL-14 Allergy Blocker Nasal Spray

Dec 8, 2025, 8:55 AM EST - 5 months ago

Polyrizon Completes FDA Pre-Submission Meeting for PL-14 Allergy Blocker Nasal Spray

From Lab to Global Impact: Polyrizon's Journey to Potentially Redefining Next-Generation Nasal Protection

Dec 4, 2025, 7:32 AM EST - 5 months ago

From Lab to Global Impact: Polyrizon's Journey to Potentially Redefining Next-Generation Nasal Protection

Polyrizon Reports Positive Mucoadhesion Results for Intranasal Naloxone Hydrogel Compared to Marketed Intranasal Naloxone product

Dec 3, 2025, 9:28 AM EST - 5 months ago

Polyrizon Reports Positive Mucoadhesion Results for Intranasal Naloxone Hydrogel Compared to Marketed Intranasal Naloxone product

Polyrizon Announces Successful Completion of Key Manufacturing Upscaling Milestone for Its Nasal Spray Platform

Dec 2, 2025, 7:55 AM EST - 5 months ago

Polyrizon Announces Successful Completion of Key Manufacturing Upscaling Milestone for Its Nasal Spray Platform

Polyrizon Demonstrates Reversible Broad-Spectrum Viral Blocking by Its Intranasal Barrier-Forming Formulation

Nov 6, 2025, 8:55 AM EST - 6 months ago

Polyrizon Demonstrates Reversible Broad-Spectrum Viral Blocking by Its Intranasal Barrier-Forming Formulation

Polyrizon Announces Positive Pre-Clinical Results: PL-14 Demonstrates Encouraging Allergen-Blocking Efficacy

Oct 6, 2025, 8:21 AM EDT - 7 months ago

Polyrizon Announces Positive Pre-Clinical Results: PL-14 Demonstrates Encouraging Allergen-Blocking Efficacy

Polyrizon Submits Pre-Sub Package to the FDA for PL-14 Allergy Blocker

Sep 19, 2025, 8:15 AM EDT - 8 months ago

Polyrizon Submits Pre-Sub Package to the FDA for PL-14 Allergy Blocker

Polyrizon Reports Successful Intranasal Delivery of PL-14 Allergy Blocker in Latest Study

Sep 12, 2025, 7:26 AM EDT - 8 months ago

Polyrizon Reports Successful Intranasal Delivery of PL-14 Allergy Blocker in Latest Study

Polyrizon Regains Compliance with Nasdaq Listing Requirements

Aug 14, 2025, 8:14 AM EDT - 9 months ago

Polyrizon Regains Compliance with Nasdaq Listing Requirements

Polyrizon Retains Nasdaq Listing Following Hearings Panel

Jul 15, 2025, 7:55 AM EDT - 10 months ago

Polyrizon Retains Nasdaq Listing Following Hearings Panel

Polyrizon Reports Promising Results Demonstrating Successful Internasal Delivery of its Innovative Hydrogel Formulation for CNS Therapeutics

Jun 12, 2025, 7:32 AM EDT - 11 months ago

Polyrizon Reports Promising Results Demonstrating Successful Internasal Delivery of its Innovative Hydrogel Formulation for CNS Therapeutics

Polyrizon Announces Receipt of Nasdaq Delisting Notice

May 23, 2025, 4:15 PM EDT - 1 year ago

Polyrizon Announces Receipt of Nasdaq Delisting Notice

Polyrizon Emerges with Positive Preclinical Data on Nasal Protection Platform

May 21, 2025, 7:10 AM EDT - 1 year ago

Polyrizon Emerges with Positive Preclinical Data on Nasal Protection Platform

Polyrizon Targets $3.15B Epilepsy Market with Preclinical Studies for Innovative Rescue Treatment

May 13, 2025, 7:45 AM EDT - 1 year ago

Polyrizon Targets $3.15B Epilepsy Market with Preclinical Studies for Innovative Rescue Treatment

Polyrizon Reports Successful Safety Study of a Formulation of PL-14 Allergy Blocker in Human Nasal Tissue Model

Apr 25, 2025, 7:37 AM EDT - 1 year ago

Polyrizon Reports Successful Safety Study of a Formulation of PL-14 Allergy Blocker in Human Nasal Tissue Model

Polyrizon Receives Nasdaq Notification Regarding Minimum Bid Requirements

Apr 11, 2025, 4:15 PM EDT - 1 year ago

Polyrizon Receives Nasdaq Notification Regarding Minimum Bid Requirements

Polyrizon Engages Leading Branding Firm for Strategic Brand Development

Apr 2, 2025, 9:05 AM EDT - 1 year ago

Polyrizon Engages Leading Branding Firm for Strategic Brand Development

Polyrizon Ltd. Announces Closing of $17.0 Million Private Placement

Apr 1, 2025, 4:09 PM EDT - 1 year ago

Polyrizon Ltd. Announces Closing of $17.0 Million Private Placement

Polyrizon Ltd. Announces $17.0 Million Private Placement

Mar 31, 2025, 9:32 AM EDT - 1 year ago

Polyrizon Ltd. Announces $17.0 Million Private Placement

Polyrizon Structures Clinical Strategy for its Allergy Blocker Ahead of FDA Pre-Submission Meeting

Mar 27, 2025, 8:25 AM EDT - 1 year ago

Polyrizon Structures Clinical Strategy for its Allergy Blocker Ahead of FDA Pre-Submission Meeting

Polyrizon Expands Drug Delivery Innovation with Preclinical Studies for Epilepsy Rescue Treatment

Mar 25, 2025, 4:04 PM EDT - 1 year ago

Polyrizon Expands Drug Delivery Innovation with Preclinical Studies for Epilepsy Rescue Treatment

Polyrizon Signs Non– Binding LOI to Expand its Innovative Intranasal Drug Delivery Platform for Psychedelic-Based Treatments

Mar 14, 2025, 8:35 AM EDT - 1 year ago

Polyrizon Signs Non– Binding LOI to Expand its Innovative Intranasal Drug Delivery Platform for Psychedelic-Based Treatments

Polyrizon Launches Preclinical Studies for Intranasal Naloxone to Combat Opioid Overdose Using Cutting-Edge Platform

Mar 13, 2025, 7:51 AM EDT - 1 year ago

Polyrizon Launches Preclinical Studies for Intranasal Naloxone to Combat Opioid Overdose Using Cutting-Edge Platform

Polyrizon Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2024

Mar 11, 2025, 4:27 PM EDT - 1 year ago

Polyrizon Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2024

Polyrizon Initiates Preclinical Studies for Intranasal Naloxone Targeting Opioid Overdose Based on Its Innovative T&T Platform

Mar 10, 2025, 7:47 AM EDT - 1 year ago

Polyrizon Initiates Preclinical Studies for Intranasal Naloxone Targeting Opioid Overdose Based on Its Innovative T&T Platform

Polyrizon Announces Filing of Divisional Patent Application for Its Innovative Trap & Target™ (T&T) Intranasal Drug Delivery Platform

Jan 30, 2025, 5:55 AM EST - 1 year ago

Polyrizon Announces Filing of Divisional Patent Application for Its Innovative Trap & Target™ (T&T) Intranasal Drug Delivery Platform

Polyrizon Commences GMP Manufacturing Preliminary Process for its PL-14 Allergy Blocker in Preparation for Planned 2025 Clinical Trial

Jan 23, 2025, 6:40 AM EST - 1 year ago

Polyrizon Commences GMP Manufacturing Preliminary Process for its PL-14 Allergy Blocker in Preparation for Planned 2025 Clinical Trial

Polyrizon Announces Publication of U.S. National Patent Application for Its Innovative Hydrogel Nasal Technologies

Dec 30, 2024, 6:25 AM EST - 1 year ago

Polyrizon Announces Publication of U.S. National Patent Application for Its Innovative Hydrogel Nasal Technologies

Tbirdyguy
Tbirdyguy May. 8 at 5:02 PM
$PLRZ looks like the market has been anticipating something big over the last 3 weeks. Solid moves today after abismal volume all week. Testing recent heights in the 17s. A pr sends this well into the 20s
0 · Reply
Shakyaasha
Shakyaasha May. 5 at 7:30 PM
$PLRZ
1 · Reply
InvestingSpaceman
InvestingSpaceman May. 4 at 9:22 PM
$BLMZ $PLRZ $BTCT.X $BTOG HL
0 · Reply
luminouslumens
luminouslumens May. 2 at 8:33 PM
$PLRZ $EUDA $ONEG $AKAN A few multi-day movers to keep an eye on Monday
0 · Reply
Tbirdyguy
Tbirdyguy Apr. 28 at 2:33 PM
$PLRZ fucking
0 · Reply
labububub
labububub Apr. 28 at 2:13 PM
$PLRZ
0 · Reply
patrick1956
patrick1956 Apr. 28 at 2:29 AM
$PLRZ ...European submission fail...FDA is not accepting their submission with any success...thus the submission at European...now both fail....look for this to head back under $10. ..imo
1 · Reply
Stock_Catcher
Stock_Catcher Apr. 28 at 2:11 AM
Treasure Tuesday Watchlist Pt.5 $OPEN $GNS $ASST $DVLT $PLRZ Let's Dominate Tomorrow
0 · Reply
StockConsultant
StockConsultant Apr. 28 at 12:14 AM
$PLRZ Polyrizon stock, watch for a range breakout at https://stockconsultant.com/?PLRZ
0 · Reply
stocktrade77
stocktrade77 Apr. 27 at 11:11 PM
$PLRZ something cooking here, taking starter for a swing to 20 / 23 - will scale in as it goes up
0 · Reply
InvestingSpaceman
InvestingSpaceman Apr. 27 at 9:41 PM
$GOOGL $SMCI $PLRZ oc
0 · Reply
Rampageusa
Rampageusa Apr. 27 at 8:33 PM
$PLRZ this was a small a small kick, we need 24/35 by Friday..
0 · Reply
Tbirdyguy
Tbirdyguy Apr. 27 at 8:01 PM
$PLRZ super fucking bullish
0 · Reply
InvestingSpaceman
InvestingSpaceman Apr. 27 at 7:57 PM
$BLMZ $PLRZ $BTCT $BTOG FMX
0 · Reply
Tbirdyguy
Tbirdyguy Apr. 27 at 7:40 PM
$PLRZ something is coming soon.
0 · Reply
Stock_Catcher
Stock_Catcher Apr. 27 at 1:28 PM
$PLRZ Polyrizon Announces Filing of European Patent Application for Its Breakthrough Drug Delivery Platform
1 · Reply
patrick1956
patrick1956 Apr. 24 at 7:35 PM
$PLRZ ..this is a no lost situation....as this is an Israel company part of the Zionist regime...they now control the CDC...which means anything they submit will pass certification...load up...guaranteed $$$
1 · Reply
Rampageusa
Rampageusa Apr. 24 at 6:30 PM
$PLRZ watching…some day 19.5/24+=
0 · Reply
Rampageusa
Rampageusa Apr. 23 at 12:18 AM
$PLRZ this sleeping giant woke up today, now looking for a big moves like 20,30s and 50s range…
1 · Reply
uptrend2025
uptrend2025 Apr. 22 at 7:30 PM
$PLRZ 🤩
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Apr. 22 at 6:28 PM
$PLRZ RSI: 58.86, MACD: -0.2198 Vol: 1.02, MA20: 11.97, MA50: 12.95 🟢 BUY - Uptrend + healthy RSI 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply